Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | F2 | P00734 | 4/20 | 0.41 |
| ▸ | REN | P00797 | 4/20 | 0.41 |
| ▸ | APLNR | P35414 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | NTSR2 | O95665 | 2/20 | 0.38 |
| ▸ | NTSR1 | P30989 | 2/20 | 0.38 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.38 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.38 |
| ▸ | MC4R | P32245 | 1/20 | 0.38 |
| ▸ | CMA1 | P23946 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31124516 | 0.89 | F2 (0.46) | F2RENAPLNRNTSR2NTSR1 | |
| SCHEMBL31124515 | 0.89 | F2 (0.46) | F2RENAPLNRNTSR2NTSR1 | |
| SCHEMBL7152157 | 0.85 | KMT2A (0.68) | KMT2AMAPK1POLBCMA1 | |
| SCHEMBL7550451 | 0.85 | KMT2A (0.68) | KMT2AMAPK1POLBCMA1 | |
| SCHEMBL31127573 | 0.84 | PSMB9 (0.42) | KMT2AF2RENAPLNRNTSR2 | |
| SCHEMBL28067690 | 0.83 | KMT2A (0.51) | KMT2AMAPK1POLBCMA1 | |
| SCHEMBL29845324 | 0.81 | REN (0.46) | RENNTSR2NTSR1 | |
| SCHEMBL31072130 | 0.81 | REN (0.46) | RENNTSR2NTSR1OPRM1 | |
| SCHEMBL30661447 | 0.81 | MC4R (0.45) | KMT2AF2RENNTSR2NTSR1 | |
| SCHEMBL29521043 | 0.79 | F2 (0.54) | F2APLNROPRM1OPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020183256-A1 | Cytostatic-integrin conjugates having specifically cleavable linking units | BAYER AKTIENGESELLSCHAFT (DE) | 2002-12-05 | — | — | US | disclosed |
| US-20020173452-A1 | Cytostatic-glycoconjugates having specifically cleavable linking units | BAYER AKTIENGESELLSCHAFT (DE) | 2002-11-21 | — | — | US | disclosed |
| WO-2002051862-A2 | CYTOSTATIC-GLYCOCONJUGATES HAVING SPECIFICALLY CLEAVABLE PEPTIDICLINKING UNITS | BAYER AKTIENGESELLSCHAFT (DE) | 2002-07-04 | — | — | WO | disclosed |
| EP-1219634-A1 | Cytostatic-glycoconjugates having specifically cleavable peptidic linking units | Bayer Aktiengesellschaft (DE) | 2002-07-03 | — | — | EP | disclosed |
| EP-1219305-A1 | Conjugates of integrin receptor antagonists and a cytostatic agent having specifically cleavable linking units | Bayer Aktiengesellschaft (DE) | 2002-07-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020173452-A1 | Cytostatic-glycoconjugates having specifically cleavable linking units | CTSE, CTSL, CTSZ | KMT2A 3269/4885F2 914/4885REN 741/4885 |
| US-20020183256-A1 | Cytostatic-integrin conjugates having specifically cleavable linking units | ITGAV, ITGB3, ITGAL | KMT2A 2966/4885F2 827/4885REN 2717/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.